论文部分内容阅读
[目的]探讨应用替罗非班对ST段抬高型急性心肌梗死患者急诊经皮冠脉介入治疗后(PCI)的临床疗效。[方法]选择某院2006年10月～2008年10月急性心梗拟行急诊PCI治疗患者54例,分为观察组(应用替罗非班)25例及对照组29例,比较两组出血并发症、血小板聚集率和1月内主要心脏不良事件。[结果]观察组血小板聚集率与对照组比较,差异有统计学意义(P﹤0.05),而出血并发症和1月内主要心脏不良事件差异无统计学意义(P﹥0.05)。[结论]应用替罗非班对ST段抬高型急性心肌梗死患者急诊经皮冠脉介入治疗后(PCI)的临床疗效显著,使用安全。
[Objective] To investigate the clinical effect of tirofiban on patients after acute percutaneous coronary intervention (PCI) in patients with ST-segment elevation acute myocardial infarction. [Methods] Choose 54 cases of acute myocardial infarction who were treated with emergency PCI from October 2006 to October 2008 in a hospital. The patients were divided into observation group (application tirofiban) 25 cases and control group 29 cases. Bleeding was compared between the two groups Complications, platelet aggregation rate and major adverse cardiac events in January. [Results] The platelet aggregation rate in the observation group was significantly different from that in the control group (P <0.05). There was no significant difference between the bleeding complications and major adverse cardiac events in January (P> 0.05). [Conclusion] The clinical effect of tirofiban on patients with ST elevation acute myocardial infarction after percutaneous coronary intervention (PCI) is significant and safe to use.